Compare TSSI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSSI | ARMP |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | 161 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 295.5M |
| IPO Year | N/A | 1996 |
| Metric | TSSI | ARMP |
|---|---|---|
| Price | $14.64 | $7.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $15.00 |
| AVG Volume (30 Days) | ★ 1.9M | 63.8K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $42.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.87 | $1.74 |
| 52 Week High | $31.94 | $14.98 |
| Indicator | TSSI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 41.35 |
| Support Level | $14.03 | $7.22 |
| Resistance Level | $16.66 | $7.93 |
| Average True Range (ATR) | 1.07 | 0.81 |
| MACD | 0.35 | 0.04 |
| Stochastic Oscillator | 63.44 | 43.72 |
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.